RWIBX
Price
$64.43
Change
-$4.56 (-6.61%)
Updated
Dec 17 closing price
RWICX
Price
$64.90
Change
-$4.63 (-6.66%)
Updated
Dec 17 closing price
Ad is loading...

RWIBX vs RWICX

Header iconRWIBX vs RWICX Comparison
Open Charts RWIBX vs RWICXBanner chart's image
American Funds Capital World Gr&Inc R2
Price$64.43
Change-$4.56 (-6.61%)
VolumeN/A
CapitalizationN/A
American Funds Capital World Gr&Inc R3
Price$64.90
Change-$4.63 (-6.66%)
VolumeN/A
CapitalizationN/A
RWIBX vs RWICX Comparison Chart
Loading...
View a ticker or compare two or three
VS
RWIBX vs. RWICX commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RWIBX is a Buy and RWICX is a Buy.

FUNDAMENTALS
Fundamentals
RWIBX (130B) and RWICX (130B) have equal amount of cash in the bank . RWICX pays higher dividends than RWIBX: RWICX (1.43) vs RWIBX (1.05). RWIBX was incepted earlier than RWICX: RWIBX (23 years) vs RWICX (23 years). RWIBX (27.00) and RWICX (27.00) have comparable annual turnover. RWIBX (250) and RWICX (250) have matching initial minimum investment requirements. RWICX (11.76) and RWIBX (11.34) have marching annual gain over last year. RWICX return over 5 years is better than : 31.34 vs. RWIBX (29.64).
RWIBXRWICXRWIBX / RWICX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence23 years23 years-
Gain YTD9.78110.19196%
Front LoadN/AN/A-
Min. Initial Investment250250100%
Min. Initial Investment IRAN/AN/A-
Net Assets130B130B100%
Annual Yield % from dividends1.051.4373%
Returns for 1 year11.3411.7696%
Returns for 3 years8.419.3390%
Returns for 5 years29.6431.3495%
Returns for 10 years44.2246.3495%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LITM0.180.03
+17.46%
Snow Lake Resources Ltd
NUVB2.810.12
+4.46%
Nuvation Bio
ENTG109.362.65
+2.48%
Entegris
ARQ7.01-0.04
-0.57%
Arq
PTCT47.02-1.59
-3.27%
PTC Therapeutics